|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Risk factors and outcomes of delayed graft function in renal transplant recipients receiving a steroid sparing immunosuppression protocol显示文摘AIM To analyse the risk factors and outcomes of delayed graft function(DGF) in patients receiving a steroid sparing protocol. METHODS Four hundred and twenty-seven recipients of deceased donor kidney transplants were studied of which 135(31.6%) experienced DGF. All patients received monoclonal antibody induction with a tacrolimus based, steroid sparing immunosuppression protocol.RESULTS Five year patient survival was 87.2% and 94.9% in the DGF and primary graft function(PGF) group respectively, P = 0.047. Allograft survival was 77.9% and 90.2% in the DGF and PGF group respectively, P < 0.001. Overall rejection free survival was no different between the DGF and PGF groups with a 1 and 5 year rejection free survival in the DGF group of 77.7% and 67.8% compared with 81.3% and 75.3% in the PGF group, P = 0.19. Patients with DGF who received IL2 receptor antibody induction were at significantly higher risk of rejection in the early post-transplant period than the group with DGF who received alemtuzumab induction. On multivariate analysis, risk factors for DGF were male recipients, recipients of black ethnicity, circulatory death donation, preformed DSA, increasing cold ischaemic time, older donor age and dialysis vintage.CONCLUSION Alemtuzumab induction may be of benefit in preventing early rejection episodes associated with DGF. Prospective trials are required to determine optimal immunotherapy protocols for patients at high risk of DGF. | Michelle Willicombe Anna Rizzello Dawn Goodall Vassilios Papalois Adam G Mc Lean David Taube | 2017 | World Journal of Transplantation2017，7，1： | 4 |
| 2 | The neuroprotective effects of heat shock protein 27 overexpression in transgenic animals against kainate-induced seizures and hippocampal cell death 显示文摘 | Mohammed T Anna MC Keliu | 2003 | J Biol Chem2003，278，19： | 1 |
| 3 | Characterization of polyploid wheat genomic diversity using a high-density 90 000 single nucleotide polymorphism array 显示文摘 | Wang SC Debbie W Kerrie F Alexandra A Shiaoman C Bevan EH Marco M Silvio S Sara GM Luigi C Anna MM Alex W Stuart S Gary B Ralf W Joerg P International Wheat Genome Sequencing Consortium Morten L Diane M Rudi A Rudy D Gina BG Abraham K Alina RA Catherine F Jerome S Michele M Curtis P Luo MC Jan DMM Jorge D Martin G Roberto T Cindy L Ivan M Colin C Keith JE Matthew H Eduard A | 2014 | Plant Biotechnol J2014，12，： | 1 |
| 4 | Wireless capsule endoscopy for obscure small - bowel final results of the first pediatric con/rolled frial 显示文摘 | Guilhon de Araujo Sant'Anna AM Dubois J Miron MC | | Clin C astroenterol Hepatol 213030，3，3： | 1 |
| 5 | Effect of valsartan on angiotensin Ⅱ-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells显示文摘 | Luigi S Anna MC Lorenzo A | 2001 | Hypertension2001，37，3： | 1 |
| 6 | Changes in open field behavior,spatial memory,and hippocampal parvalbumin immunoreactivity following enrichment in rats exposed to neonatal anoxia显示文摘 | Iuvone L Geloso MC Dell’Anna E | 1996 | Exp Neurol1996，139，： | 1 |
| 7 | Unerupted second primary mandibular molar positioned inferior to the second premolar: case report显示文摘 | Borsatto MC Sant'Anna AT Niero H | 1999 | Pediatr Dent1999，21，3： | 1 |
| 8 | Gatrointestinal mesenchymal tumors-immunophenotypic classification and survival analysis 显示文摘 | PierreR Anna MC Ursula P | 2002 | Virch Arch2002，411，3： | 1 |
| 9 | Polymorphisms in the oxidized low-density lipoprotein receptor-1 gene and risk of Alzheimer's disease显示文摘 | Alessia D I Vincenzo S Anna MC | 2005 | Journals of Gerontology2005，60，3： | 1 |
| 10 | Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1显示文摘AIM: To evaluate daclatasvir vs telaprevir, each combined with peginterferon alfa-2a/ribavirin(peg IFN/RBV), in treatment-naive hepatitis C virus(HCV) genotype(GT) 1-infected patients.METHODS: In this phase 3, randomized, open-label, noninferiority study, 602 patients were randomly assigned(2:1) to daclatasvir vs telaprevir, stratified by IL28 B rs12979860 host genotype(CC vs non-CC), cirrhosis status(compensated cirrhosis vs no cirrhosis), and HCV GT1 subtype(GT1a vs GT1b). Patients were selected by study inclusion criteria from a total of 793 enrolled patients. Patients received daclatasvir 60 mg once daily or telaprevir 750 mg 3 times daily plus peg IFN/RBV. Daclatasvir recipients received 24 wk of daclatasvir plus peg IFN/RBV; those without an extended rapid virologic response(e RVR; undetectable HCV-RNA at weeks 4 and 12) received an additional 24 wk of peg IFN/RBV. Telaprevir-treated patients received 12 wk of telaprevir plus peg IFN/RBV followed by 12(with e RVR) or 36(no e RVR) wk of peg IFN/RBV. The primary objective was to compare for noninferiority of sustained virologic response rates at posttreatment week 12(SVR12) in GT1b-infected patients. Key secondary objectives were to demonstrate that the rates of anemia(hemoglobin < 10 g/d L) and rashrelated events, through week 12, were lower with daclatasvir + peg IFN/RBV than with telaprevir + peg IFN/RBV among GT1b-infected patients. Resistance testing was performed using population-based sequencing of the NS5 A region for all patients at baseline, and for patients with virologic failure or relapse and HCV-RNA ≥ 1000 IU/m L, to investigate any link between NS5 A polymorphisms associated with daclatasvir resistance and virologic outcome. RESULTS: Patient demographics and disease characteristics were generally balanced across treatment arms; however, there was a higher proportion of black/African Americans in the daclatasvir groups(6.0% and 8.2% in the GT1 b and GT1 a groups, respectively) than in the telaprevir groups(2.2% and 3.0%). Among GT1 binfected patients, daclatasvir plus peg IFN/RBV was noninferior to telaprevir plus peg IFN/RBV for SVR12 [85%(228/268) vs 81%(109/134); difference, 4.3%(95%CI:-3.3% to 11.9%)]. Anemia(hemoglobin < 10 g/d L) was significantly less frequent with daclatasvir than with telaprevir [difference,-29.1%(95%CI:-38.8% to-19.4%)]. Rash-related events were also less common with daclatasvir than with telaprevir, but the difference was not statistically significant. In GT1 ainfected patients, SVR12 was 64.9% with daclatasvir and 69.7% with telaprevir. Among both daclatasvir and telaprevir treatment groups, across GT1b- or GT1a-infected patients, lower response rates were observed in patients with IL28 B non-CC and cirrhosis- factors known to affect response to peg IFN/RBV. Consistent with these observations, a multivariate logistic regression analysis in GT1b-infected patients d e m o n s t ra t e d t h a t S V R 1 2 wa s a s s o c i a t e d w i t h IL28 B host genotype(CC vs non-CC, P = 0.011) and cirrhosis status(absent vs present, P = 0.031). NS5 A polymorphisms associated with daclatasvir resistance(at L28, R30, L31, or Y93) were observed in 17.3% of GT1b-infected patients at baseline; such variants did not appear to be absolute predictors of failure since 72.1% of these patients achieved SVR12 compared with 86.9% without these polymorphisms. Among GT1b-infected patients, treatment was completed by 85.4%(229/268) in the daclatasvir group, and by 85.1%(114/134) in the telaprevir group, and among GT1a-infected patients, by 67.2%(90/134) and 69.7%(46/66), respectively. Discontinuations(of all 3 agents) due to an AE were more frequent with telaprevir than with daclatasvir, whereas discontinuations due to lack of efficacy were more frequent with daclatasvir, due, in part, to differences in futility criteria. CONCLUSION: Daclatasvir plus peg IFN/RBV demonstrated noninferiority to telaprevir plus peg IFN/RBV for SVR12 and was well-tolerated in treatment-naive GT1 binfected patients, supporting the use of daclatasvir with other direct-acting antivirals. | Ira Jacobson Stefan Zeuzem Robert Flisiak Brygida Knysz Stefan Lueth Dorota Zarebska-Michaluk Ewa Janczewska Peter Ferenci Moises Diago Anna Linda Zignego Rifaat Safadi Yaacov Baruch Dzhamal Abdurakhmanov Stephen Shafran Dominique Thabut Rafael Bruck Adrian Gadano Alexander James Thompson Justin Kopit Fiona Mc Phee Tracy Michener Eric A Hughes Philip D Yin Stephanie Noviello | 2016 | World Journal of Gastroenterology2016，22，12： | 1 |
| 11 | Thoracoscopic Water P|eurectomy for the Treatment of Recurrent Spontaneous Pneumo- thorax 显示文摘 | Claudio A Antonio DA Anna MC et al | 2014 | Ann Thorac Surg2014，12，5： | 1 |
| 12 | Novel biomarkers for pre-dicting pre-eclampsia显示文摘 | David MC Christian D Anna FD | 2008 | Trends in Cardiovascular Medicine2008，18，5： | 1 |
| 13 | Right ventricular pacing impairs endothelial function in man显示文摘 | Anna MC Henry HM Douglas HJ | 2011 | Europace2011，13，6： | 1 |
| 14 | Exposure to perfluorinated compounds in Catalonia, Spain, through consumption of various raw and cooked foodstuffs, including packaged food显示文摘 | Ericson IJ Gemma P Xavier L Esther B Roser MC Anna K Jose LD | 2009 | Food and Chemical Toxicology2009，47，： | 1 |
| 15 | Gastrointestinal mesenchymal tumors-immunophenotypic classification and survival analysis 显示文摘 | PierreR Anna MC Ursula P | 2002 | VirchArch2002，411，3： | 1 |
| 16 | The sequence and antiapoptotic functional domains of the human cytomegalovirus UL37 of TRAIL exon I immediate early protein are conserved in multiple primary strains 显示文摘 | Wail AH Anamaris MC Anna S | 2001 | Virology2001，279，： | 1 |
| 17 | Wireless capsule endoscopy for obscure small-bowel disorders final results of the first pediatric controlled trial 显示文摘 | Guilhon de Araujo Sant'Anna AM Dubois J Miron MC | 2005 | Clin Gastro- enterol Hepatol2005，3，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员